Skip to content
OpenCapital
Get started

ANI Pharmaceuticals ANIP Available-for-Sale Debt Securities - Amortized Cost

Available-for-Sale Debt Securities - Amortized Cost at other companies

Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$586.4M-6.6%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$357.25M—
Amgen logo
AmgenAMGN
——

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.89B+18.3%
Enterprise value$1.88B+5.8%
P/E20.5×—
P/S2×-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%—
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiCost.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's available-for-sale debt securities - amortized cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's available-for-sale debt securities - amortized cost?
ANI Pharmaceuticals (ANIP) reported available-for-sale debt securities - amortized cost of $14.89M in Q1 2026.
How has ANI Pharmaceuticals's available-for-sale debt securities - amortized cost changed year-over-year?
ANI Pharmaceuticals's available-for-sale debt securities - amortized cost increased by 176.4% year-over-year, from $5.39M to $14.89M.
What does available-for-sale debt securities - amortized cost mean?
This is the cost basis of debt securities classified as available-for-sale, adjusted for amortization of premiums or discounts. It represents the value of the investment portfolio before accounting for current market price fluctuations. This provides a baseline for evaluating the performance of the company's liquid investment strategy.